<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519567</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-1601-102</org_study_id>
    <nct_id>NCT04519567</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia</brief_title>
  <official_title>A Phase 1 Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Larimar Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veristat, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Metrum Research Group, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Larimar Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of multiple ascending doses of CTI-1601 in&#xD;
      participants with Friedreich's ataxia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple Ascending Dose (MAD), Double-Blind, Placebo Controlled Study.&#xD;
&#xD;
      To evaluate the safety and tolerability of multiple ascending doses of CTI-1601 in subjects&#xD;
      with Friedreich's ataxia.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To evaluate the pharmacokinetics (PK) of CTI-1601 following, multiple, increasing, doses&#xD;
           of subcutaneously (SC) administered CTI-1601.&#xD;
&#xD;
        2. To evaluate the pharmacodynamics (PD) of CTI-1601 following, multiple, increasing, doses&#xD;
           of SC administered CTI-1601.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2020</start_date>
  <completion_date type="Actual">March 16, 2021</completion_date>
  <primary_completion_date type="Actual">March 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment Emergent Adverse Events</measure>
    <time_frame>Through study completion, an average of 75 days</time_frame>
    <description>Overall summary of Participants with Treatment Emergent Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Treatment Emergent Adverse Events by System Organ Classification and Preferred Term</measure>
    <time_frame>Through study completion, an average of 75 days</time_frame>
    <description>Overall summary of Participants with Treatment Emergent Adverse Events by System Organ Classification (MedDRA version 23.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Maximum observed plasma concentration after multiple doses</measure>
    <time_frame>At baseline and up to 15 days</time_frame>
    <description>Summary assessment of changes in the maximum observed plasma concentration after multiple doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Minimum or &quot;trough&quot; plasma concentration after multiple doses</measure>
    <time_frame>At baseline and up to 15 days</time_frame>
    <description>Summary assessment of minimum or &quot;trough&quot; observed plasma concentration after multiple doses just prior to the administration of a subsequent dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under the concentration time curve (AUC) from time 0 through the last measurable time point</measure>
    <time_frame>At baseline and up to 15 days</time_frame>
    <description>Summary assessment of changes in the AUC from time 0 to the last measurable time point and during the dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Terminal half-life estimation</measure>
    <time_frame>At baseline and up to 15 days</time_frame>
    <description>Summary assessment of changes in the terminal half-life estimation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Frataxin Levels in Buccal Cell</measure>
    <time_frame>At baseline and up to 43 days</time_frame>
    <description>Summary assessment of changes in frataxin levels in buccal cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Levels of Protein Markers in Buccal Cell</measure>
    <time_frame>At baseline and up to 43 days</time_frame>
    <description>Summary assessment of changes in levels of protein markers in buccal cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Gene Expression in Buccal Cells</measure>
    <time_frame>At baseline and up to 43 days</time_frame>
    <description>Summary assessment of changes in gene expression in buccal cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Frataxin Levels in Platelets</measure>
    <time_frame>At baseline and up to 13 days</time_frame>
    <description>Summary assessment of changes in frataxin levels in platelets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Gene Expression in Whole Blood</measure>
    <time_frame>At baseline and up to 16 days</time_frame>
    <description>Summary assessment of changes in gene expression in whole blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Frataxin Levels in Skin Punch Cells</measure>
    <time_frame>At baseline and up to 13 days</time_frame>
    <description>Summary assessment of changes in frataxin levels in skin punch cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Levels of Defined Protein Markers in Blood</measure>
    <time_frame>At baseline and up to 16 days</time_frame>
    <description>Summary assessment of changes in levels of defined protein markers in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Levels of Specialized Lipids in Blood</measure>
    <time_frame>At baseline and up to 16 days</time_frame>
    <description>Summary assessment of changes in levels of specialized lipids in blood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>CTI-1601</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTI-1601</intervention_name>
    <description>CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia</description>
    <arm_group_label>CTI-1601</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has genetically confirmed Friedreich's ataxia diagnosis manifested by&#xD;
             homozygous GAA repeat expansions, with repeat sizing (if available) included on&#xD;
             diagnostic report.&#xD;
&#xD;
          2. Subject is male or female, 18 years of age or older at screening&#xD;
&#xD;
          3. Subject must have a mFARS_neuro score â‰¥ 20 and be able to traverse a distance of 25&#xD;
             feet with or without some assistive device (cane, walker, crutches, self-propelled&#xD;
             wheelchair) and (a) be able to sit upright with thighs together and arms crossed&#xD;
             without requiring support on more than two sides; (b) be able to transfer from bed to&#xD;
             chair independently or with assistance if, in the opinion of the principal&#xD;
             investigator, the degree of physical disability does not result in undue risk to the&#xD;
             subject while participating in the study; and (c) perform basic daily care, such as&#xD;
             feeding themselves and personal hygiene, with minimal assistance.&#xD;
&#xD;
          4. Subjects must weigh &gt; 40 kilograms (kg).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who had a serious adverse event (SAE), an adverse event (AE) that is Grade 3&#xD;
             or higher according to the Common Terminology Criteria for Adverse Events (CTCAE),&#xD;
             version 5.0 (or higher), or an AE considered clinically significant during&#xD;
             participation in CLIN-1601-101 (NCT04176991).&#xD;
&#xD;
          2. Subjects who are confirmed as compound heterozygous (GAA repeat expansion on only one&#xD;
             allele) for Friedreich's ataxia.&#xD;
&#xD;
          3. Subject use of investigational drug (other than CTI-1601) or device within 90 days&#xD;
             prior to screening.&#xD;
&#xD;
          4. Subject requires use of amiodarone.&#xD;
&#xD;
          5. Subject used erythropoietin, etravirine, or gamma interferon within 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          6. Subject use of daily biotin supplementation that exceeds 30 mcg/day, either as part of&#xD;
             a multivitamin or as a standalone supplement, within 7 days prior to study drug&#xD;
             administration and/or throughout the entire study.&#xD;
&#xD;
          7. Subject has clinically significant arrhythmia on electrocardiogram (ECG), or evidence&#xD;
             of predisposition to significant ventricular arrhythmia on ECG, or evidence of active&#xD;
             and unstable coronary artery disease.&#xD;
&#xD;
          8. Male subject who has a QT interval corrected for heart rate using Fridericia's formula&#xD;
             (QTcF) &gt; 450 milliseconds or female subject who has a QTcF &gt; 470 milliseconds on an&#xD;
             ECG.&#xD;
&#xD;
          9. Subject has a screening echocardiogram left ventricular ejection fraction &lt; 45&#xD;
             percent.&#xD;
&#xD;
         10. Subject has a history of aspiration, aspiration pneumonia, or recurrent episodes of&#xD;
             pneumonia (greater than or equal to 2 episodes of pneumonia) within the last 12&#xD;
             months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdy Shenouda, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinilabs, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinilabs Drug Development Corporation</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.curefa.org/</url>
    <description>Friedreich's Ataxia Research Alliance</description>
  </link>
  <reference>
    <citation>Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011 Apr 15;303(1-2):1-12. doi: 10.1016/j.jns.2011.01.010. Review.</citation>
    <PMID>21315377</PMID>
  </reference>
  <reference>
    <citation>Delatycki MB, Corben LA. Clinical features of Friedreich ataxia. J Child Neurol. 2012 Sep;27(9):1133-7. doi: 10.1177/0883073812448230. Epub 2012 Jun 29. Review.</citation>
    <PMID>22752493</PMID>
  </reference>
  <reference>
    <citation>Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil. 1988 Oct;69(10):850-4.</citation>
    <PMID>3178453</PMID>
  </reference>
  <reference>
    <citation>Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Clinical outcomes assessment in multiple sclerosis. Ann Neurol. 1996 Sep;40(3):469-79. Review.</citation>
    <PMID>8797541</PMID>
  </reference>
  <reference>
    <citation>Plasterer HL, Deutsch EC, Belmonte M, Egan E, Lynch DR, Rusche JR. Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxia. PLoS One. 2013 May 17;8(5):e63958. doi: 10.1371/journal.pone.0063958. Print 2013.</citation>
    <PMID>23691127</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

